Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 48

Results For "BAL-Pharma"

594 News Found

Glenmark launches Lobeglitazone in India for Uncontrolled Type 2 Diabetes in adults
News | October 07, 2022

Glenmark launches Lobeglitazone in India for Uncontrolled Type 2 Diabetes in adults

Glenmark is the first company in India to launch Thiazolidinedione Lobeglitazone (0.5 mg).


Lupin appoints Dr. Shahin Fesharaki as Global Chief Scientific Officer
People | October 07, 2022

Lupin appoints Dr. Shahin Fesharaki as Global Chief Scientific Officer

Dr. Fesharaki most recently served as the Chief Scientific Officer and Global Head of R&D for Hikma Pharmaceuticals.


Moderna creates new executive committee role for product launches
News | October 04, 2022

Moderna creates new executive committee role for product launches

Juan Andres Appointed to President, Strategic Partnerships and Enterprise Expansion


Lupin Life announces association with Vikram Vedha as official energy partner
News | October 02, 2022

Lupin Life announces association with Vikram Vedha as official energy partner

Enriched with eight ayurvedic active ingredients like Ashwagandha, Shilajit, Shatavari, and Pippali, Be One works holistically to provide energy, build immunity and enable a healthy body and mind


Lupin receives US FDA approval for Mirabegron Extended-Release tablets
Drug Approval | September 30, 2022

Lupin receives US FDA approval for Mirabegron Extended-Release tablets

Mirabegron Extended-Release Tablets, 25 mg and 50 mg, had estimated annual sales of US $2.4 billion in US


Lupin launches Sildenafil for Oral Suspension in US
Drug Approval | September 30, 2022

Lupin launches Sildenafil for Oral Suspension in US

Sildenafil for Oral Suspension (RLD Revatio) had estimated annual sales of US $64 million in the US


Lupin receives approval from US FDA for Diclofenac Sodium Topical Solution USP
Drug Approval | September 23, 2022

Lupin receives approval from US FDA for Diclofenac Sodium Topical Solution USP

Diclofenac Sodium Topical Solution USP, 2% w/w (RLD Pennsaid) had estimated annual sales of US $484 million in the US


Pharmexcil to organise exhibition on pharma and healthcare on Sept 21-23
News | September 16, 2022

Pharmexcil to organise exhibition on pharma and healthcare on Sept 21-23

The event is supported by the Ministry of Commerce & Industry, Government of India and CDSCO, Ministry of Health.


Dr. Jaidev Rajpal appointed MD & CEO of Jubilant Generics
People | September 15, 2022

Dr. Jaidev Rajpal appointed MD & CEO of Jubilant Generics

He has over two decades of rich experience in management consulting, advising and transforming leading generic pharmaceutical companies in India and global markets


Lupin receives Health Canada approval for Rymti
Drug Approval | September 14, 2022

Lupin receives Health Canada approval for Rymti

Rymti is indicated in the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, axial spondyloarthritis, plaque psoriasis, and paediatric plaque psoriasis